Biotech company developing cutting-edge benchtop protein printing technologies
Nuclera has raised €133M across 5 funding rounds from 19 investors, most recently a Series C round in Jan 2026. Based in Cambridge, UK; active in Healthtech. Data as of 6 Aug 2026.
Timing: in window vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2026-01-13 | Series C | €10M | British Business Bank,Elevage Medical Technologies,GK Goh,Jonathan Milner | View deal → |
| 2024-10-16 | Series A | €69M | Cambridge Innovation Capital,E Ink Holdings,Elevage Medical Technologies,GK Goh,Jonathan Milner,M&G Catalyst+4 more | View deal → |
| 2024-06-06 | Grant | €1.3M | Innovate UK | View deal → |
| 2022-07-06 | Series B | €15M | Jonathan Milner,Verve Ventures | View deal → |
| 2022-02-02 | Series B | €38M | Amadeus Capital Partners,British Business Bank Future Fund,E Ink,Future Planet Capital,G. K. Goh,M&G Investments+1 more | View deal → |
